ADE and dengue vaccination

Vaccine

Volumn 35, Issue 32, 2017, Pages 3910-3912

  Martínez Vega, Ruth Aralí ^a   Carrasquila, Gabriel ^b   Luna, Expedito ^c   Ramos Castañeda, José ^d,e  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Dengue; Immunity; Pathogenesis; Vaccine

Indexed keywords

CD40 LIGAND; DENGUE VACCINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR;

CLINICAL EFFECTIVENESS; DENGUE; EPIDEMIOLOGICAL DATA; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; NOTE; PRIORITY JOURNAL; VACCINE PRODUCTION; ANTIBODY DEPENDENT ENHANCEMENT; DENGUE VIRUS; IMMUNOLOGY; STATISTICAL MODEL; VACCINATION;

ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; MODELS, STATISTICAL; VACCINATION;

EID: 85020722037     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.06.004     Document Type: Note

References (23)

1. Pang, T., SAGE committee advice on dengue vaccine. Lancet Infect Dis 16 (2016), 880–882.
2. Halstead, S.B., Russell, P.K., Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 34 (2016), 1643–1647.
3. Halstead, S.B., Licensed dengue vaccine: public health conundrum and scientific challenge. Am J Trop Med Hyg 95 (2016), 741–745.
4. Halstead, S.B., Dengue vaccine efficacy: not a zero sum game. J Infect Dis, 2016.
5. Halstead, S.B., Critique of world health organization recommendation of a dengue vaccine. J Infect Dis, 2016.
6. Hadinegoro, S.R., Arredondo-Garcia, J.L., Guy, B., Bouckenooghe, A., Noriega, F., Jackson, N., Answer to the review from Halstead and Russell “Protective and immunological behavior of chimeric yellow fever dengue vaccine”. Vaccine 34 (2016), 4273–4274, 10.1016/j.vaccine.2016.02.004.
7. Arredondo-Garcia, J.L., Hadinegoro, S.R., Guy, B., Bouckenooghe, A., Noriega, F., Jackson, N., Is discussion of dengue vaccination for the 2016 Olympics necessary?. Lancet 388 (2016), 1880–1881.
8. Wilder-Smith, A., Vannice, K.S., Hombach, J., Farrar, J., Nolan, T., Population perspectives and World Health Organization recommendations for CYD-TDV dengue vaccine. J Infect Dis, 2016.
9. Halstead, S.B., Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42 (1970), 350–362.
10. Chevillon, C., Failloux, A.B., Questions on viral population biology to complete dengue puzzle. Trends Microbiol 11 (2003), 415–421.
11. Deparis, X., A new approach to dengue epidemiology: sequential infection and ADE hypothesis—the story of a dogma. KMaB, P., (eds.) Molecular biology of the flavivirus, 2006, United Kingdom Horizon Bioscience, 135–168.
12. SAGE/WHO. Background paper on dengue vaccines; 2016.
13. Hadinegoro, S.R., Arredondo-Garcia, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
14. Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 14 (2016), 45–54.
15. Iani, F.C., Caldas, S., Duarte, M.M., Cury, A.L., Cecilio, A.B., Costa, P.A., et al. Dengue patients with early hemorrhagic manifestations lose coordinate expression of the anti-inflammatory cytokine IL-10 with the inflammatory cytokines IL-6 and IL-8. Am J Trop Med Hyg 95 (2016), 193–200.
16. Harenberg, A., de Montfort, A., Jantet-Blaudez, F., Bonaparte, M., Boudet, F., Saville, M., et al. Cytokine profile of children hospitalized with virologically-confirmed dengue during two phase III vaccine efficacy trials. PLoS Negl Trop Dis, 10, 2016, e0004830.
17. Duong, V., Lambrechts, L., Paul, R.E., Ly, S., Lay, R.S., Long, K.C., et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci USA, 2015.
18. Olivera-Botello, G., Coudeville, L., Fanouillere, K., Guy, B., Chambonneau, L., Noriega, F., et al. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2–16 years in Asia and Latin America. J Infect Dis 214 (2016), 994–1000.
19. TAG/PAHO. XXIV meeting of the technical advisory group on vaccine-preventable diseases; 2016.
20. Ferguson, N.M., Rodriguez-Barraquer, I., Dorigatti, I., Mier, Y.T.-R.L., Laydon, D.J., Cummings, D.A., Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science 353 (2016), 1033–1036.
21. Organization PAH. Dengue. Washington D.C. USA; 2016.
22. Villar, L., Dayan, G.H., Arredondo-García, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. New England J Med 372 (2015), 113–123.
23. Gessner, B.D., Wilder-Smith, A., Estimating the public health importance of the CYD-tetravalent dengue vaccine: vaccine preventable disease incidence and numbers needed to vaccinate. Vaccine 34 (2016), 2397–2401.